Vivatides Lands $54M to Unlock RNA Therapies Beyond the Liver

SUZHOU, China and BOSTON – April 10, 2026 – Vivatides Therapeutics, a biotechnology startup with a bold mission to redefine the boundaries of genetic medicine, has secured a landmark $54 million in an oversubscribed Series A financing round. The funding signals powerful investor belief in the company's potential to solve one of the most significant challenges in modern drug development: delivering RNA-based therapies to tissues beyond the liver.

The financing, announced today, was co-led by the prominent Qiming Venture Partners and an undisclosed leading industry fund. The round also saw participation from Highlight Capital, TF Capital, and continued support from seed investor Apricot Capital. The capital injection will fuel the advancement of Vivatides' proprietary delivery platform, push multiple drug candidates toward clinical trials, and support a global expansion of its research and development teams. For a company founded just last year in 2025, securing both seed and Series A funding in under twelve months highlights the immense confidence the investment community has in its technology and leadership.

The Extrahepatic Frontier

RNA therapeutics represent a revolutionary third pillar of medicine, standing alongside small molecules and antibody-based drugs. Their ability to precisely target the genetic roots of disease offers unprecedented specificity and long-lasting effects. However, the field has been constrained by a major biological hurdle: delivery. The vast majority of existing RNA drugs, such as those using small interfering RNA (siRNA), naturally accumulate in the liver. While this has led to groundbreaking treatments for liver-associated diseases, it leaves a vast landscape of human ailments—from cardiovascular conditions to cancer and neurological disorders—largely untouched by this powerful modality.

This is the challenge Vivatides was created to solve. The company is developing what it calls an "extrahepatic" delivery platform, designed to act as a transport system for RNA drugs to reach specific tissues and organs throughout the body.

"Extrahepatic delivery is the key that will unlock RNA therapeutics from niche rare diseases to broad chronic indications," said Keming Zhou, Founder of Vivatides Therapeutics, in a statement. "We believe that overcoming delivery barriers will enable RNA therapeutics to transform treatment paradigms across a wide range of diseases."

The company's platform is built to support two leading types of RNA medicine: siRNA and antisense oligonucleotides (ASO). By innovating in areas like ligand conjugation—where a targeting molecule is attached to the drug to act like a biological GPS—Vivatides has already demonstrated encouraging results in preclinical models, showing improved delivery efficiency, tissue specificity, and a strong safety profile.

A Vote of Confidence from Top Investors

The oversubscribed nature of the $54 million round is a clear indicator of the perceived value of Vivatides' approach. In a competitive biotech funding environment, attracting more capital than sought is a testament to the company's compelling science and experienced team.

Lead investor Qiming Venture Partners, a firm known for early bets on titans like ByteDance and Xiaomi, has a strong track record in the healthcare sector. Their involvement lends significant credibility to Vivatides' long-term vision.

"We have long been optimistic about the application potential of small nucleic acid drugs across a broader range of disease areas," commented Dr. Kan Chen, a Partner at Qiming Venture Partners. "Continuous advances in extrahepatic targeting technologies are steadily expanding their clinical frontiers. Vivatides Therapeutics has demonstrated solid technological expertise and efficient execution capabilities in this field."

This sentiment was echoed by Apricot Capital, which backed the company in its initial seed round. "Since its founding, Dr. Zhou and his team have consistently exceeded expectations with exceptional execution in platform development and pipeline advancement," said Dr. Wei Ding, Partner at Apricot Capital. This continued financial backing from early investors underscores the tangible progress the company has made in a short time.

Navigating a Competitive and Promising Landscape

Vivatides enters a field of intense scientific and commercial interest. Pioneers like Alnylam Pharmaceuticals, which successfully commercialized the first RNAi drugs, are also actively working to expand beyond the liver, exploring targets in the central nervous system and lungs. Other companies are developing novel delivery vehicles, from advanced lipid nanoparticles (LNPs) to peptide-based systems, all vying to crack the extrahepatic code.

However, Vivatides' key advantage may lie in its people. The company's leadership team is comprised of seasoned experts from the very companies that built the RNA therapeutics field, including Alnylam, Arrowhead Pharmaceuticals, and Ionis Pharmaceuticals. According to the company, this team has direct experience leading multiple extrahepatic RNA programs that have already reached clinical development, providing them with invaluable, hard-won insights into the complexities of next-generation drug design. This unique concentration of practical experience in a technically demanding niche sets Vivatides apart.

Unlocking a Multi-Billion Dollar Market

The ultimate promise of solving the extrahepatic delivery problem is the ability to address some of the most prevalent and challenging diseases facing humanity. The global market for RNA therapeutics, valued at over $8.5 billion in 2025, is projected to soar to nearly $29 billion by 2035. Much of that growth is expected to come from expanding into new therapeutic areas.

Vivatides has set its sights on high-prevalence chronic diseases like hyperlipidemia (high cholesterol), hypertension (high blood pressure), and oncology. The RNA-based oncology drug market alone is forecast to grow at a staggering rate, with some projections estimating it will exceed $15 billion by 2031. By developing therapies that can target cancer cells directly or address the root causes of cardiovascular disease in tissues outside the liver, Vivatides is positioning itself to compete in some of the largest segments of the pharmaceutical market.

With its new funding, the company plans to aggressively advance its most promising programs through preclinical optimization and into the formal IND-enabling studies required to begin human trials. It will also expand its R&D and management teams in both Suzhou and Boston, strengthening its transatlantic operational footprint. This strategic infusion of capital marks a critical inflection point for Vivatides as it moves from a promising startup to a clinical-stage contender in the quest to realize the full potential of genetic medicine.